amitiza Drug Patent Profile
✉ Email this page to a colleague
When do Amitiza patents expire, and when can generic versions of Amitiza launch?
Amitiza is a drug marketed by Sucampo Pharma Llc and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.
This drug has seventy-two patent family members in nineteen countries.
The generic ingredient in AMITIZA is lubiprostone. There are ten drug master file entries for this compound. Sixteen suppliers are listed for this compound. Additional details are available on the lubiprostone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Amitiza
A generic version of amitiza was approved as lubiprostone by AMNEAL on November 30th, 2021.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for amitiza?
- What are the global sales for amitiza?
- What is Average Wholesale Price for amitiza?
Summary for amitiza
| International Patents: | 72 |
| US Patents: | 5 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 10 |
| Raw Ingredient (Bulk) Api Vendors: | 87 |
| Clinical Trials: | 28 |
| Patent Applications: | 1,244 |
| Drug Prices: | Drug price information for amitiza |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for amitiza |
| What excipients (inactive ingredients) are in amitiza? | amitiza excipients list |
| DailyMed Link: | amitiza at DailyMed |
Recent Clinical Trials for amitiza
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Sucampo AG | Phase 2 |
| Takeda | Phase 2 |
| Sucampo Pharma Americas, LLC | Phase 2 |
Pharmacology for amitiza
| Drug Class | Chloride Channel Activator |
| Mechanism of Action | Chloride Channel Activators |
Paragraph IV (Patent) Challenges for AMITIZA
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| AMITIZA | Capsules | lubiprostone | 8 mcg and 24 mcg | 021908 | 1 | 2012-08-20 |
US Patents and Regulatory Information for amitiza
amitiza is protected by six US patents.
Patents protecting amitiza
Method for treating abdominal discomfort
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD FOR TREATING IRRITABLE BOWEL SYNDROME AND METHOD FOR TREATING ABDOMINAL DISCOMFORT ASSOCIATED WITH IRRITABLE BOWEL SYNDROME
Soft-gelatin capsule formulation
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Soft-gelatin capsule formulation
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Method for treating gastrointestinal disorder
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT WITH IRRITABLE BOWEL SYNDROME
Method for treating gastrointestinal disorder
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD FOR THE LONG TERM TREATMENT OF CHRONIC CONSTIPATION IN A HUMAN SUBJECT
Soft-gelatin capsule formulation
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-002 | Apr 29, 2008 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-001 | Jan 31, 2006 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-002 | Apr 29, 2008 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for amitiza
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-001 | Jan 31, 2006 | ⤷ Sign Up | ⤷ Sign Up |
| Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-002 | Apr 29, 2008 | ⤷ Sign Up | ⤷ Sign Up |
| Sucampo Pharma Llc | AMITIZA | lubiprostone | CAPSULE;ORAL | 021908-002 | Apr 29, 2008 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for amitiza
When does loss-of-exclusivity occur for amitiza?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 07208632
Patent: Soft-gelatin capsule formulation
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 0707334
Patent: formulação de cápsula de gelatila mole e método para estabilização de um composto 15-cetoprostaglandina
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 37274
Patent: FORMULATION DE CAPSULE GELATINEUSE MOLLE (SOFT-GELATIN CAPSULE FORMULATION)
Estimated Expiration: ⤷ Sign Up
China
Patent: 1410097
Patent: Soft-gelatin capsule formulation
Estimated Expiration: ⤷ Sign Up
Patent: 4971056
Patent: Soft-gelatin Capsule Formulation
Estimated Expiration: ⤷ Sign Up
Patent: 4983712
Patent: SOFT-GELATIN CAPSULE FORMULATION
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 78944
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 78944
Patent: FORMULATION DE CAPSULE GELATINEUSE MOLLE (SOFT-GELATIN CAPSULE FORMULATION)
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 2867
Patent: הרכב קפסולת ג'לטין רך (Soft-gelatin capsule formulation)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 83794
Estimated Expiration: ⤷ Sign Up
Patent: 08534432
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 08009650
Patent: FORMULACION DE CAPSULA DE GELATINA SUAVE. (SOFT-GELATIN CAPSULE FORMULATION.)
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 0191
Patent: Soft-gelatin capsule formulation comprising a keto-prostaglandin compound
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 78944
Estimated Expiration: ⤷ Sign Up
Russian Federation
Patent: 20291
Patent: СОСТАВ В МЯГКОЙ ЖЕЛАТИНОВОЙ КАПСУЛЕ (COMPOSITION IN SOFT GELATIN CAPSULE)
Estimated Expiration: ⤷ Sign Up
Patent: 08134489
Patent: СОСТАВ В МЯГКОЙ ЖЕЛАТИНОВОЙ КАПСУЛЕ
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 1393944
Estimated Expiration: ⤷ Sign Up
Patent: 080090526
Patent: SOFT-GELATIN CAPSULE FORMULATION
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 92590
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering amitiza around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Japan | 4684334 | ⤷ Sign Up | |
| Russian Federation | 2694361 | КОМПОЗИЦИЯ СЛАБИТЕЛЬНОГО СРЕДСТВА | ⤷ Sign Up |
| Japan | 2006513232 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for amitiza
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1315485 | 132016000025193 | Italy | ⤷ Sign Up | PRODUCT NAME: LUBIPROSTONE O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE(AMITIZA); AUTHORISATION NUMBER(S) AND DATE(S): PL 21341/0003, 20120910;043833019-021, 20150526 |
| 1315485 | 49/2015 | Austria | ⤷ Sign Up | PRODUCT NAME: LUBIPROSTON UND PHARMAZEUTISCH ANNEHMBARE SALZE DAVON; NAT. REGISTRATION NO/DATE: 136176 20150508; FIRST REGISTRATION: GB PL 21341/0003 20120910 |
| 1315485 | C300757 | Netherlands | ⤷ Sign Up | PRODUCT NAME: LUBIPROSTON; NAT. REGISTRATION NO/DATE: RVG 115891 20150317; FIRST REGISTRATION: |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
